



KINEXUS

Kinexus Named a 2002 Venture All Star Company

The Pacific Northwest's Venture Event of the Year Honored Kinexus Bioinformatics Corporation as one of the Top Venture-Backed Companies in the Region

FOR IMMEDIATE RELEASE SEPTEMBER 30, 2002

VANCOUVER, British Columbia - Kinexus Bioinformatics Corporation has been honored as a 2002 Venture All Star by the Investment Forum, a non-profit organization that promotes promising new companies to the business and investment community. Mr. David Turner, Chief Executive Officer of Kinexus, was honored along with 38 other Northwest CEOs last night at the Pacific Northwest's venture event of the year honoring the top venture-backed companies in the region held at the Seahawks Stadium. Kinexus was also featured in the third edition of The Venture Map, the definitive visual business reference, which will be distributed to more than 30,000 private investors and top business executives throughout the Northwest including Oregon and British Columbia.

"We were thrilled to be honored by the Seattle Investment Forum" said Mr. David Turner, Chief Executive Officer for Kinexus, "especially since Kinexus was one of only three biotechnology companies chosen from British Columbia. Kinexus has a unique business model and proprietary technology that generates revenue and expedites drug discovery for academia and biopharmaceutical companies around the world," he added.

The 2002 Venture All Star companies were selected over a six week period from more than 125 nominations by a 35 member Selection Committee comprised representatives from the region's top venture capital funds and private investors. To be selected, these companies had to meet multiple business and funding criteria indicative of future success including strong management and financial backing. For a complete list of the companies, visit: www.TheVentureMap.com.

"Kinexus has proven its ability to be a leader and prosper in a difficult economic environment," said Nathan McDonald, Chair of the 2002 Venture All Stars and Investment Forum. "We're honored to produce the third-annual Venture All Stars event to recognize and promote companies with outstanding growth prospects."

Kinexus is a discovery-driven, signal transduction company that develops innovative strategies to understand intracellular communication systems involving protein kinases. These enzymes are the key proteins responsible for communication and control inside cells, and their malfunction has been linked to more than 400 human diseases including cancer, diabetes and cardiovascular disease. Kinexus provides innovative proteomics solutions to industrial and academic clients using standardized immunoblotting screens. This proprietary technology is faster and more sensitive for specific detection of cell signalling proteins, more versatile for different species, more reproducible than conventional proteomics methods, and provides clients with potential leads to identify disease markers and drug targets, characterize drug leads, and validate appropriate animal markers of human disease.

For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at www.kinexus.ca.

PRESS RELEASE - 2002 SEPTEMBER 30